Thrombin Confers Chemotherapeutic Resistance by Promoting Transcriptional Induction and Post-translational Stabilization of Pro-survival MCL1 in TNBC

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2024 Nov 28

PMID 39608719

Authors

Subhojit Paul

Akash Chatterjee

Kaushik Das

Anushka Ray

Abhimanyu Basu

Soma Mukhopadhyay

Prosenjit Sen

Affiliations

Soon will be listed here.

Abstract

The association between idiopathic venous thrombosis and occult cancer is widely recognized. However, the comprehensive understanding of how thrombin, generated during the process of thrombosis, possesses the potential to augment the malignant phenotype is still not well understood. The coagulation protease thrombin mediates its effects by cleaving protease-activated receptor 1 (PAR1), a receptor abundantly expressed on the surface of triple-negative breast cancer (TNBC) cells. While emerging evidence implicates coagulation proteases in facilitating cancer progression, the precise molecular pathways underlying thrombin-mediated induction of chemoresistance remain poorly defined. Here, we demonstrate that thrombin-induced PAR1 activation in TNBC cells promotes the development of a multidrug-resistant phenotype, mechanistically linked to the upregulation of the pro-survival protein MCL1. Genetic ablation of MCL1 sensitizes TNBC cells to cytotoxic drugs despite thrombin exposure, affirming MCL1's functional importance. Chromatin immunoprecipitation analyses reveal thrombin triggers protein kinase A-dependent phosphorylation of serine 133 residues of cAMP-responsive element-binding protein (CREB), enhancing CREB's affinity for the co-activators CBP and p300. Furthermore, thrombin treatment induces the nuclear translocation of CREB-regulated transcription coactivator 2 (CRTC2) in a calcium-dependent manner, which collectively interacts with CREB/CBP-P300. The coordinated action of these transcriptional co-activators facilitates the transcriptional induction of MCL1. We further report that PAR1 activation augments MCL1 binding to the deubiquitinase USP9X, reducing MCL1 turnover. Our pre-clinical breast cancer murine model also shows that genetic deletion of PAR1 sensitizes breast cancer cells to chemotherapeutic drugs in vivo. Collectively, these findings emphasize the thrombin-PAR1 axis as a novel driver of chemoresistance. Utilizing FDA-approved oral anticoagulants for selective blocking of thrombin action may serve as a potential therapeutic adjunct for the treatment of triple-negative breast cancer.

References

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J . The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363. PMC: 9597512. DOI: 10.3389/fonc.2022.985363. View

Bhandari B, Mehta B . Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!. Recent Adv Cardiovasc Drug Discov. 2015; 9(2):73-7. DOI: 10.2174/1574890110666150624100815. View

Maurer U, Charvet C, Wagman A, Dejardin E, Green D . Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006; 21(6):749-60. DOI: 10.1016/j.molcel.2006.02.009. View

Laviv T, Scholl B, Parra-Bueno P, Foote B, Zhang C, Yan L . In Vivo Imaging of the Coupling between Neuronal and CREB Activity in the Mouse Brain. Neuron. 2019; 105(5):799-812.e5. PMC: 7144870. DOI: 10.1016/j.neuron.2019.11.028. View

Ogryzko V, Schiltz R, Russanova V, Howard B, Nakatani Y . The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996; 87(5):953-9. DOI: 10.1016/s0092-8674(00)82001-2. View

Ahmed M, Alghamdi A, Islam S, Lee J, Lee Y . cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach. Cells. 2022; 11(13). PMC: 9266045. DOI: 10.3390/cells11132020. View

Mojsa B, Lassot I, Desagher S . Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells. 2014; 3(2):418-37. PMC: 4092850. DOI: 10.3390/cells3020418. View

Wang Y, Liao R, Chen X, Ying X, Chen G, Li M . Twist-mediated PAR1 induction is required for breast cancer progression and metastasis by inhibiting Hippo pathway. Cell Death Dis. 2020; 11(7):520. PMC: 7347637. DOI: 10.1038/s41419-020-2725-4. View

De Guzman R, Goto N, Dyson H, Wright P . Structural basis for cooperative transcription factor binding to the CBP coactivator. J Mol Biol. 2005; 355(5):1005-13. DOI: 10.1016/j.jmb.2005.09.059. View

10.

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

11.

Yilmaz D, Kirschner K, Demirci H, Himmerkus N, Bachmann S, Mutig K . Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022; 298(3):101589. PMC: 8857494. DOI: 10.1016/j.jbc.2022.101589. View

12.

Naqvi S, Martin K, Arthur J . CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. Biochem J. 2014; 458(3):469-79. DOI: 10.1042/BJ20131115. View

13.

Franzoi M, Saude-Conde R, Cristovao Ferreira S, Eiger D, Awada A, de Azambuja E . Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. Breast. 2021; 57:86-94. PMC: 8044724. DOI: 10.1016/j.breast.2021.03.002. View

14.

Monroe D, Hoffman M, Roberts H . Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002; 22(9):1381-9. DOI: 10.1161/01.atv.0000031340.68494.34. View

15.

Obidiro O, Battogtokh G, Akala E . Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. 2023; 15(7). PMC: 10384267. DOI: 10.3390/pharmaceutics15071796. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Screaton R, Conkright M, Katoh Y, Best J, Canettieri G, Jeffries S . The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004; 119(1):61-74. DOI: 10.1016/j.cell.2004.09.015. View

18.

Senichkin V, Streletskaia A, Gorbunova A, Zhivotovsky B, Kopeina G . Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020; 27(2):405-419. PMC: 7206148. DOI: 10.1038/s41418-019-0486-3. View

19.

Beurel E, Grieco S, Jope R . Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2014; 148:114-31. PMC: 4340754. DOI: 10.1016/j.pharmthera.2014.11.016. View

20.

Nierodzik M, Karpatkin S . Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10(5):355-62. DOI: 10.1016/j.ccr.2006.10.002. View